Division Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Victoria, Australia.
Ann Oncol. 2013 May;24(5):1344-51. doi: 10.1093/annonc/mds623. Epub 2013 Jan 4.
We evaluated the long-term results of radiotherapy for patients with gastric marginal zone lymphoma (GMZL).
We carried out a retrospective, multi-centre study of patients with low-grade GMZL treated by radiotherapy between 17 July 1981 and 25 March 2004.
There were 102 eligible patients. Fifty-eight patients were previously untreated and 44 had recurrent/residual disease after prior treatment (HP eradication, chemotherapy and surgery in 35, 9 and 8 patients, respectively, and 7 had >1 prior therapy). Radiation fields included the stomach /involved nodes in 61 patients and whole abdomen in 41. The median radiotherapy dose to stomach was 40 Gy (range 26-46 Gy) in a median 22 fractions. With a median follow-up after radiotherapy of 7.9 years (range 0.3-24 years), 10- and 15-year freedom from treatment failure (FFTF) was 88% (95% CI 82%-95%). Risk factors for TF were a large-cell component (P = 0.036) and an exophytic growth pattern (P = 0.042). Radiotherapy field size, radiotherapy dose, and failure of prior therapy were not associated with inferior FFTF. Ten-year overall survival was 70% (95% CI 60%-82%).
Radiotherapy achieves cure for the majority of patients with low-grade GMZL, including patients who have had prior therapy. Several features may predict a poorer outcome.
我们评估了胃黏膜相关边缘区淋巴瘤(GMZL)患者放疗的长期疗效。
我们进行了一项回顾性多中心研究,纳入了 1981 年 7 月 17 日至 2004 年 3 月 25 日期间接受放疗的低级别 GMZL 患者。
共有 102 例符合条件的患者。58 例患者为初治患者,44 例患者为先前治疗后复发/残留疾病(分别有 35、9 和 8 例患者接受了幽门螺杆菌根除、化疗和手术治疗,7 例患者接受了 >1 种先前治疗)。61 例患者的照射野包括胃/受累淋巴结,41 例患者的照射野为全腹部。胃的中位放疗剂量为 40 Gy(范围 26-46 Gy),中位分割 22 次。放疗后中位随访 7.9 年(范围 0.3-24 年),10 年和 15 年无治疗失败(FFTF)率分别为 88%(95%CI 82%-95%)。TF 的危险因素包括大细胞成分(P=0.036)和外生性生长模式(P=0.042)。照射野大小、放疗剂量和先前治疗失败与较差的 FFTF 无关。10 年总生存率为 70%(95%CI 60%-82%)。
放疗可治愈大多数低级别 GMZL 患者,包括先前接受过治疗的患者。一些特征可能预示着预后不良。